Chun-Ming Tsai

7.3k total citations · 1 hit paper
60 papers, 3.2k citations indexed

About

Chun-Ming Tsai is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Chun-Ming Tsai has authored 60 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Oncology, 47 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Chun-Ming Tsai's work include Lung Cancer Treatments and Mutations (44 papers), Lung Cancer Research Studies (33 papers) and Lung Cancer Diagnosis and Treatment (23 papers). Chun-Ming Tsai is often cited by papers focused on Lung Cancer Treatments and Mutations (44 papers), Lung Cancer Research Studies (33 papers) and Lung Cancer Diagnosis and Treatment (23 papers). Chun-Ming Tsai collaborates with scholars based in Taiwan, United States and South Korea. Chun-Ming Tsai's co-authors include Reury-Perng Perng, Chong‐Jen Yu, Yuh-Min Chen, James Chih‐Hsin Yang, Jacqueline Whang‐Peng, Tony Mok, Sai‐Hong Ignatius Ou, Lecia V. Sequist, Sarayut Lucien Geater and Martin Schüler and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and ACS Applied Materials & Interfaces.

In The Last Decade

Chun-Ming Tsai

60 papers receiving 3.1k citations

Hit Papers

Clinical activity of afatinib in patients with advanced n... 2015 2026 2018 2022 2015 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
    2015 715 citations James Chih‐Hsin Yang, Chun-Ming Tsai et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chun-Ming Tsai Taiwan 27 2.4k 2.2k 744 507 163 60 3.2k
Michele Aieta Italy 24 997 0.4× 1.2k 0.5× 638 0.9× 600 1.2× 315 1.9× 116 2.3k
Noe Kyeong Kim South Korea 24 1.4k 0.6× 1.7k 0.8× 988 1.3× 367 0.7× 401 2.5× 60 3.4k
Sang Won Shin South Korea 26 950 0.4× 1.2k 0.6× 551 0.7× 306 0.6× 253 1.6× 122 2.5k
J.C. Soria France 21 980 0.4× 1.4k 0.6× 1.0k 1.3× 528 1.0× 226 1.4× 124 2.8k
Kathryn A. Gold United States 29 1.8k 0.8× 2.1k 1.0× 922 1.2× 463 0.9× 338 2.1× 99 3.5k
Melinda S. Merchant United States 25 730 0.3× 1.3k 0.6× 850 1.1× 248 0.5× 102 0.6× 56 2.8k
Mitra Tewes Germany 19 795 0.3× 1.8k 0.8× 863 1.2× 884 1.7× 99 0.6× 73 2.6k
Yaxiong Zhang China 22 1.1k 0.5× 1.5k 0.7× 382 0.5× 327 0.6× 217 1.3× 75 2.1k
Alexander J. Chou United States 25 1.1k 0.5× 726 0.3× 931 1.3× 503 1.0× 241 1.5× 61 2.4k
Steven Powell United States 21 1.6k 0.7× 2.6k 1.2× 426 0.6× 305 0.6× 575 3.5× 91 3.6k

Countries citing papers authored by Chun-Ming Tsai

Since Specialization
Citations

This map shows the geographic impact of Chun-Ming Tsai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chun-Ming Tsai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chun-Ming Tsai more than expected).

Fields of papers citing papers by Chun-Ming Tsai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chun-Ming Tsai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chun-Ming Tsai. The network helps show where Chun-Ming Tsai may publish in the future.

Co-authorship network of co-authors of Chun-Ming Tsai

This figure shows the co-authorship network connecting the top 25 collaborators of Chun-Ming Tsai. A scholar is included among the top collaborators of Chun-Ming Tsai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chun-Ming Tsai. Chun-Ming Tsai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nishio, Makoto, Enriqueta Felip, Sergey Orlov, et al.. (2019). Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC. Journal of Thoracic Oncology. 15(4). 609–617. 28 indexed citations
2.
Scagliotti, Giorgio V., Denis Moro‐Sibilot, Jens Kollmeier, et al.. (2019). A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients. Journal of Thoracic Oncology. 15(1). 80–90. 60 indexed citations
3.
Chen, Hui‐Mei, Chun-Ming Tsai, Yu–Chung Wu, Kuan‐Chia Lin, & Chia‐Chin Lin. (2016). Effect of walking on circadian rhythms and sleep quality of patients with lung cancer: a randomised controlled trial. British Journal of Cancer. 115(11). 1304–1312. 64 indexed citations
4.
Chen, Hui‐Mei, Yu–Chung Wu, Chun-Ming Tsai, Jann-Inn Tzeng, & Chia‐Chin Lin. (2014). Relationships of Circadian Rhythms and Physical Activity With Objective Sleep Parameters in Lung Cancer Patients. Cancer Nursing. 38(3). 215–223. 32 indexed citations
5.
Luo, Yung‐Hung, Hsiang‐Ling Ho, Chun-Ming Tsai, et al.. (2013). The Association Between Tumor Epidermal Growth Factor Receptor (EGFR) Mutation and Multiple Primary Malignancies in Patients With Adenocarcinoma of the Lungs. American Journal of Clinical Oncology. 38(2). 147–151. 10 indexed citations
6.
Chiou, Guang‐Yuh, Jong‐Yuh Cherng, Han‐Shui Hsu, et al.. (2012). Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial–mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma. Journal of Controlled Release. 159(2). 240–250. 118 indexed citations
7.
Chen, Yuh-Min, Chun-Ming Tsai, Shih-Hao Liu, et al.. (2011). A Phase II Randomized Trial of Gefitinib Alone or with Tegafur/Uracil Treatment in Patients with Pulmonary Adenocarcinoma Who had Failed Previous Chemotherapy. Journal of Thoracic Oncology. 6(6). 1110–1116. 23 indexed citations
8.
Yu, Chong‐Jen, Chun-Ming Tsai, Ming-Shyan Huang, et al.. (2010). Different Efficacies of Erlotinib and Gefitinib in Taiwanese Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Multicenter Study. Journal of Thoracic Oncology. 6(1). 148–155. 26 indexed citations
9.
Maïo, Massimo Di, Nicola Lama, Alessandro Morabito, et al.. (2010). Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual data of nine randomised trials. European Journal of Cancer. 46(4). 735–743. 50 indexed citations
10.
Chien, Chun‐Ru, et al.. (2008). Quality of Care for Lung Cancer in Taiwan: A Pattern of Care Based on Core Measures in the Taiwan Cancer Database Registry. Journal of the Formosan Medical Association. 107(8). 635–643. 12 indexed citations
11.
Wang, Shu‐Yi, Chun-Ming Tsai, Bing-Chang Chen, Chien‐Huang Lin, & Chia‐Chin Lin. (2008). Symptom Clusters and Relationships to Symptom Interference with Daily Life in Taiwanese Lung Cancer Patients. Journal of Pain and Symptom Management. 35(3). 258–266. 72 indexed citations
12.
Chen, Yuh-Min, Jen-Fu Shih, Reury-Perng Perng, Chun-Ming Tsai, & Jacqueline Whang‐Peng. (2006). A Randomized Trial of Different Docetaxel Schedules in Non-small Cell Lung Cancer Patients Who Failed Previous Platinum-Based Chemotherapy. CHEST Journal. 129(4). 1031–1038. 80 indexed citations
13.
Perng, Reury-Perng, Chih‐Yi Chen, Gee‐Chen Chang, et al.. (2006). Revisit of 1997 TNM Staging System—Survival Analysis of 1112 Lung Cancer Patients in Taiwan. Japanese Journal of Clinical Oncology. 37(1). 9–15. 11 indexed citations
14.
Abratt, Raymond P., Ji Youn Han, Chun-Ming Tsai, et al.. (2006). Phase II Trial of Gemcitabine-Carboplatin-Paclitaxel as Neoadjuvant Chemotherapy for Operable Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 1(2). 135–140. 11 indexed citations
15.
Chen, Yuh-Min, Reury-Perng Perng, Chun-Ming Tsai, & Jacqueline Whang‐Peng. (2006). A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. Lung Cancer. 52(3). 333–338. 7 indexed citations
16.
Chen, Yuh-Min, Reury-Perng Perng, Jen-Fu Shih, Chun-Ming Tsai, & Jacqueline Whang‐Peng. (2005). Chemotherapy for Non-small Cell Lung Cancer in Elderly Patients. CHEST Journal. 128(1). 132–139. 12 indexed citations
17.
Chang, Kuo-Ting, et al.. (2005). Role of IL-6 in neuroendocrine differentiation and chemosensitivity of non-small cell lung cancer. American Journal of Physiology-Lung Cellular and Molecular Physiology. 289(3). L438–L445. 17 indexed citations
18.
Chen, Yuh-Min, et al.. (2003). Phase II Study of Gemcitabine and Vinorelbine Combination Chemotherapy in Patients With Non–Small-Cell Lung Cancer Not Responding to Previous Chemotherapy. American Journal of Clinical Oncology. 26(6). 567–570. 15 indexed citations
19.
20.
Brauch, Hiltrud, Tor Knutsen, B. E. Johnson, et al.. (1995). Molecular genetic characterization of neuroendocrine lung cancer cell lines.. PubMed. 15(2). 225–32. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michele Aieta Breakdown of academic impact, for papers by Noe Kyeong Kim Breakdown of academic impact, for papers by Sang Won Shin Breakdown of academic impact, for papers by J.C. Soria Breakdown of academic impact, for papers by Kathryn A. Gold Breakdown of academic impact, for papers by Melinda S. Merchant Breakdown of academic impact, for papers by Mitra Tewes Breakdown of academic impact, for papers by Yaxiong Zhang Breakdown of academic impact, for papers by Alexander J. Chou Breakdown of academic impact, for papers by Steven Powell
Rankless by CCL
2026